elranatamab will enhance the level or outcome of fentanyl transdermal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on. Elranatamab causes cytokine launch syndrome (CRS) which could suppress activity of CYP enzymes, leading to improved exposure of CYP substrates.brivaracetam and fentanyl transdermal the two raise